company background image
ALT logo

Altimmune NasdaqGM:ALT Stock Report

Last Price

US$10.18

Market Cap

US$630.3m

7D

11.7%

1Y

141.2%

Updated

28 Mar, 2024

Data

Company Financials +

ALT Stock Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

ALT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Altimmune, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share PriceUS$10.18
52 Week HighUS$14.84
52 Week LowUS$2.09
Beta0.069
1 Month Change-26.29%
3 Month Change-9.51%
1 Year Change141.23%
3 Year Change-27.29%
5 Year Change221.14%
Change since IPO-95.71%

Recent News & Updates

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Recent updates

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17
Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Aug 06
We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Altimmune: NASH And Obesity At The End Of The COVID Tunnel

Jul 27

Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers

Jun 16

Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study

May 26

Altimmune reports encouraging AdCOVID data in SARS-CoV-2 challenged mice

May 10

We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth

May 02
We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth

Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%

Mar 21
Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%

Analysts Expect Breakeven For Altimmune, Inc. (NASDAQ:ALT) Before Long

Feb 28
Analysts Expect Breakeven For Altimmune, Inc. (NASDAQ:ALT) Before Long

Shareholder Returns

ALTUS BiotechsUS Market
7D11.7%0.9%0.2%
1Y141.2%11.0%28.1%

Return vs Industry: ALT exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: ALT exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement17.6%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ALT's share price has been volatile over the past 3 months.

Volatility Over Time: ALT's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199759Vipin Garghttps://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune, Inc. Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT fundamental statistics
Market capUS$630.26m
Earnings (TTM)-US$88.45m
Revenue (TTM)US$426.00k

1,694x

P/S Ratio

-8.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALT income statement (TTM)
RevenueUS$426.00k
Cost of RevenueUS$65.80m
Gross Profit-US$65.37m
Other ExpensesUS$23.07m
Earnings-US$88.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.25
Gross Margin-15,345.77%
Net Profit Margin-20,762.21%
Debt/Equity Ratio0%

How did ALT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.